Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. - Wikidata - wikimedia - TriplyDB

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

http://www.wikidata.org/entity/Q34557866

about

Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages Erlotinib for advanced pancreatic cancer Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer Recent progress in pancreatic cancer Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer Curcumin AntiCancer Studies in Pancreatic Cancer Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment Prognostic value of lymph node metastases detected during surgical exploration for pancreatic or periampullary cancer: a systematic review and meta-analysis Systemic Chemotherapy in Advanced Pancreatic Cancer Local Ablative Strategies for Ductal Pancreatic Cancer (Radiofrequency Ablation, Irreversible Electroporation): A Review Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians Management of pancreatic cancer in the elderly Albumin-bound paclitaxel in solid tumors: clinical development and future directions Neoadjuvant therapy for localized pancreatic cancer: guiding principles Management of borderline and locally advanced pancreatic cancer: where do we stand?Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles Systemic treatment for inoperable pancreatic adenocarcinoma: review and update Interplay between smoking-induced genotoxicity and altered signaling in pancreatic carcinogenesis Systemic therapies for pancreatic cancer--the role of pharmacogenetics Pancreatic cancer treatment and research: an international expert panel discussion.Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer?Can Molecular Biomarkers Change the Paradigm of Pancreatic Cancer Prognosis?Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer Immunotherapy for patients with advanced pancreatic carcinoma: A promising treatment Genetic factors affecting patient responses to pancreatic cancer treatment Metastatic pancreatic cancer: Is there a light at the end of the tunnel?The Triple-Code Model for Pancreatic Cancer: Cross Talk Among Genetics, Epigenetics, and Nuclear Structure Advances in chemotherapy for pancreatic cancer Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis Predictive modeling of in vivo response to gemcitabine in pancreatic cancer Clinical Translation of Nanomedicine.Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment.Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison.Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study.Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone.Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer.Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses.

P2860

Q21092323-74A79A50-6B3A-486A-80F1-BD18516A9373 Q24186983-9D6D73FC-ED97-40DF-9DA2-C4417D67ECA1 Q24240739-8A853140-E054-4B1C-9370-D3E2178A23D4 Q24245085-FCA5AFA7-A318-4AA5-8547-F78042AE30C2 Q24626346-DF980298-E378-4DF7-9C2C-203A78D5E43C Q24627664-8BF49405-9737-4AB0-B982-DADB4232FF9D Q24631880-F9B57C49-0D6B-4B69-9C6B-DB1C408123BF Q26738714-41C9A289-E2AF-4A11-B497-9B584A71680A Q26740619-95D097D0-679F-44C9-9685-37BEFDB76753 Q26747108-DB2212D5-6CA0-450D-B60E-BC22EA6FBC62 Q26750440-7B86AD45-5161-4748-9457-3C0EF53596FB Q26765288-85E37AA3-317C-43E3-BEC6-A5002DD019D9 Q26767041-C3516836-1BE6-41BB-A9FA-4F1E7028D1B9 Q26774639-609CCBC3-6DD3-4516-A048-50A6F6023647 Q26798674-A63A9CD3-85FB-473F-AFF7-95C268C3C438 Q26799428-E604514A-5E43-4FBA-ABF8-9EF62C6B2F4A Q26825414-3D8C52D3-54EE-4B85-8B28-AFB2329763DB Q26828959-A168E1CB-EDA1-43CA-A983-EBD2E0436D43 Q26830913-470DFE1B-7102-40E9-BB32-F6EABC3E102C Q26996794-C9E83EE7-7DA9-497D-8E66-E190B9DC6E19 Q27021716-151D8585-E30D-4272-A47E-2955BF90FCAF Q27690868-FD157C24-AE4A-4C45-95E8-D88AD4CF70CD Q28066268-6BAD91BC-6D2A-48C9-93BF-92D466872026 Q28066454-64248448-F2FA-4E70-A90B-7C3E323BC811 Q28072210-9CE16BF2-96C3-4B90-BF6C-64AC40B55E22 Q28074428-26C4A167-6D5D-4EF6-8741-4DA5FE70AA97 Q28075293-1ABCD2EB-30E7-4782-9780-2F7BC3D5698E Q28082919-564ADCC5-6485-47FE-86F0-2CDF75D6A9F3 Q28084785-5F6E072B-291F-4C54-A943-766047E8FFE0 Q28085711-444CE902-1B64-4885-BABE-5EB7C175AB5F Q28487656-E8A078E3-1F4B-4BDC-AD0A-927178CC881B Q28533633-B6912A03-B528-404D-853A-461FF91E0F0E Q30355939-94F1BB70-5A5F-4318-BB21-B09035D4B7D7 Q30424344-C9C2B069-A510-437A-983A-7A2621722992 Q33326148-813D0AD7-4111-4308-9B58-470EA0B2ED59 Q33350085-06EDAEAF-7F62-402D-83EA-55D45EE59289 Q33371000-A24F6532-A34A-4743-8572-100B01F3E3D1 Q33373308-CCFB8D46-BE5D-483A-B230-A1EC3FE1E845 Q33378968-EFB9F8E2-99E9-41C4-B0E9-369DA22BF0C2 Q33380084-5127CFA2-89C2-444D-B5B3-EB5A20070007

P2860

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

http://www.wikidata.org/entity/Q34557866

description

2005 nî lūn-bûn

@nan

2005 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Gemcitabine in combination wit ...... OR and GISCAD phase III trial.

@ast

Gemcitabine in combination wit ...... OR and GISCAD phase III trial.

@en

Gemcitabine in combination wit ...... OR and GISCAD phase III trial.

@nl

type

label

Gemcitabine in combination wit ...... OR and GISCAD phase III trial.

@ast

Gemcitabine in combination wit ...... OR and GISCAD phase III trial.

@en

Gemcitabine in combination wit ...... OR and GISCAD phase III trial.

@nl

prefLabel

Gemcitabine in combination wit ...... OR and GISCAD phase III trial.

@ast

Gemcitabine in combination wit ...... OR and GISCAD phase III trial.

@en

Gemcitabine in combination wit ...... OR and GISCAD phase III trial.

@nl

P1433

Q34557866-4C35919C-4A16-44C4-B9AD-7692A128267A

P1476

Q34557866-45D25DD9-7C52-4EDA-B5D2-7A7AA34BD54D

P2093

Q34557866-196953F9-309C-425B-85C4-8EF68B70EA71

Q34557866-2B648969-A187-48EE-A9EA-2A230A686741

Q34557866-347333FE-534B-4054-B701-23FB61109711

Q34557866-3BA7A13C-9FFA-4D01-9A9E-29D6FA9A2E11

Q34557866-4E5C522D-0A8F-4833-88EC-223B60DACA17

Q34557866-566267CC-AA6B-49F2-9559-AAA1E7D274A9

Q34557866-70723F5B-B856-431F-BF93-164649729365

Q34557866-88D65193-2D7E-40AB-A164-8255B4A60389

Q34557866-A06DB9A7-8898-47DD-989E-18E6643B6F1C

Q34557866-A9141E25-181F-4E7F-8E79-D88948523409

P304

Q34557866-DD7A4C22-72AB-469F-B47E-B3EA5A4E0E5A

P31

Q34557866-D1E0BFC6-4079-4CC5-A67E-0F791DD2713A

P356

Q34557866-2A8D78CD-FCDD-41E6-9C74-0AD85E8144FE

P407

Q34557866-4B9F470F-6753-48EC-92D4-A262F7128AFE

P433

Q34557866-89D6943B-05C5-4AF1-BF10-DB67E1C9D35A

P478

Q34557866-2243D3F7-2A87-43D8-A1D3-29116BF35B30

P50

Q34557866-18063FEC-05BF-431D-A6CD-6BA9E25196B5

Q34557866-D84C264F-6B59-4BFC-A0CC-EE4A8771C9EC

Q34557866-DD73377B-3269-40D5-BD65-A679BBFF0931

P577

Q34557866-AAAE7A0D-5B4A-4A6D-A050-9ED17EE2232A

P698

Q34557866-96E7B46C-534E-4550-B9F7-6D7A9D2D7A59

P921

Q34557866-68AFC043-A661-4F5E-8E1D-15AE9791FC96

P356

JCO.2005.06.023

P1433

Journal of Clinical Oncology

P1476

Gemcitabine in combination wit ...... COR and GISCAD phase III trial

@en

P2093

A Zaniboni

http://www.w3.org/2001/XMLSchema#string

A de Gramont

http://www.w3.org/2001/XMLSchema#string

C Lepere

http://www.w3.org/2001/XMLSchema#string

C Louvet

http://www.w3.org/2001/XMLSchema#string

E Aitini

http://www.w3.org/2001/XMLSchema#string

G Lledo

http://www.w3.org/2001/XMLSchema#string

GERCOR

http://www.w3.org/2001/XMLSchema#string

GISCAD

http://www.w3.org/2001/XMLSchema#string

J Taïeb

http://www.w3.org/2001/XMLSchema#string

M Ducreux

http://www.w3.org/2001/XMLSchema#string

P304

3509-3516

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.06.023

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Roberto Labianca

P577

2005-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15908661

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial